Anastassia Anastassopoulou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anastassia Anastassopoulou has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Aikaterini Bilitou
Daiichi Sankyo Europe GmbH, Munich, Germany
1 shared publication - Alfred von Krempelhuber
GSK, Munich, Germany
1 shared publication - Barbara Poulsen Nautrup
EAH-Consulting, Aachen, Germany
1 shared publication - Bernhard Ultsch
GSK, Munich, Germany
1 shared publication C. Teixeira
Medical Affairs, Daiichi Sankyo Portugal, Porto Salvo, Portugal
1 shared publication- Christine Poulos
RTI Health Solutions, Research Triangle Park, USA
1 shared publication
Latest Publications
- Open Access
- 29 August 2023
- Published by Elsevier in Atherosclerosis
- Vol. 379, S124-S125
Gender differences in attainment of LDL-C goals independently of treatment intensity
- 29 August 2023
- Published by Elsevier in Atherosclerosis
- Vol. 379, S124-S125
Open AccessGender differences in attainment of LDL-C goals independently of treatment intensity
- Open Access
- 14 October 2022
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 39 (1) , 1-11
Treatment and low-density lipoprotein cholesterol levels in patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular risk: a population-based cross-sectional study in the Netherlands
Objective: To describe treatment patterns, low-density lipoprotein cholesterol (LDL-C) levels and healthcare resource utilization (HCRU) in the Netherlands in 2018 of patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular (CV) risk. Methods: From the PHARMO Database Network adult patients with a diagnosis for hypercholesterolaemia or mixed dyslipidaemia or treated with lipid lowering therapy (LLT) between 2009 and 2018 were selected and the proportion at high or very high CV risk according to 2016 ESC/EAS guidelines was determined. The study population comprised patients at high or very high CV risk for whom LDL-C levels were recorded and who were treated with LLT or were characterized as statin intolerant in 2018. LLT treatment patterns, LDL-C levels and HCRU (GP consultations and hospitalizations) were assessed. Results: The study population included 54,346 patients with hypercholesterolaemia/mixed dyslipidaemia, of which 70% (37,978) were at very high CV risk and 30% (16,368) at high CV risk. The majority of patients (93%) were treated with statin monotherapy, consisting mostly (73%) of moderate intensity and 15% of high intensity statin. Only 3% were treated with a combination of statin and ezetimibe. Statin intolerance, based on a treatment algorithm, was estimated at 3%. Average LDL-C decreased with intensification of LLT with more intensive statins or combination therapy. Overall, 74% reached LDL-C Conclusion: The treatment of hypercholesterolaemia and mixed dyslipidaemia in patients at high or very high CV risk in the Netherlands was suboptimal in 2018. To further lower CV risk alternative treatment strategies using add-on therapies are needed.
- 14 October 2022
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 39 (1) , 1-11
Open AccessTreatment and low-density lipoprotein cholesterol levels in patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular risk: a population-based cross-sectional study in the Netherlands
Objective: To describe treatment patterns, low-density lipoprotein cholesterol (LDL-C) levels and healthcare resource utilization (HCRU) in the Netherlands in 2018 of patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular (CV) risk. Methods: From the PHARMO Database Network adult patients with a diagnosis for hypercholesterolaemia or mixed dyslipidaemia or treated with lipid lowering therapy (LLT) between 2009 and 2018 were selected and the proportion at high or very high CV risk according to 2016 ESC/EAS guidelines was determined. The study population comprised patients at high or very high CV risk for whom LDL-C levels were recorded and who were treated with LLT or were characterized as statin intolerant in 2018. LLT treatment patterns, LDL-C levels and HCRU (GP consultations and hospitalizations) were assessed. Results: The study population included 54,346 patients with hypercholesterolaemia/mixed dyslipidaemia, of which 70% (37,978) were at very high CV risk and 30% (16,368) at high CV risk. The majority of patients (93%) were treated with statin monotherapy, consisting mostly (73%) of moderate intensity and 15% of high intensity statin. Only 3% were treated with a combination of statin and ezetimibe. Statin intolerance, based on a treatment algorithm, was estimated at 3%. Average LDL-C decreased with intensification of LLT with more intensive statins or combination therapy. Overall, 74% reached LDL-C Conclusion: The treatment of hypercholesterolaemia and mixed dyslipidaemia in patients at high or very high CV risk in the Netherlands was suboptimal in 2018. To further lower CV risk alternative treatment strategies using add-on therapies are needed.
- Open Access
- 29 April 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2058304
Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany
Seasonal influenza causes many cases and related deaths in Europe annually, despite ongoing vaccination programs for older adults and people at high-risk of complications. Children have the highest risk of infection and play a key role in disease transmission. Our cost-utility analysis, based on a dynamic transmission model, estimated the impact of increasing the current vaccination coverage with inactivated quadrivalent influenza vaccine in Germany to all (healthy and high-risk) children under 5 years of age (40% uptake), or under 18 years (40% uptake), or only high-risk children under 18 years (90% uptake). Eight influenza complications were modeled, hospitalization and death rates were based on age and risk status. All three vaccination strategies provided more health benefits than the existing vaccination situation, reducing influenza cases, complications, hospitalizations and deaths across the entire population. The strategy targeting all children under 5 years was highly cost-effective (€6/quality-adjusted life-year gained, payer perspective). The other strategies were cost saving from the payer and societal perspectives. The vaccination strategy targeting all children under 18 years was estimated to provide the most health benefits (preventing on average 1.66 million cases, 179,000 complications, 14,000 hospitalizations and 3,600 deaths due to influenza annually) and the most cost savings (annually €20.5 million and €731.3 million from payer and societal perspectives, respectively). Our analysis provides policy decision-makers with evidence supporting strategies to expand childhood influenza vaccination, to directly protect children, and indirectly all other unvaccinated age groups, in order to reduce the humanistic and economic burden on healthcare systems and society. What is the context? What is new? What is the impact?
- 29 April 2022
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 18 (5) , 2058304
Open AccessCost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany
Seasonal influenza causes many cases and related deaths in Europe annually, despite ongoing vaccination programs for older adults and people at high-risk of complications. Children have the highest risk of infection and play a key role in disease transmission. Our cost-utility analysis, based on a dynamic transmission model, estimated the impact of increasing the current vaccination coverage with inactivated quadrivalent influenza vaccine in Germany to all (healthy and high-risk) children under 5 years of age (40% uptake), or under 18 years (40% uptake), or only high-risk children under 18 years (90% uptake). Eight influenza complications were modeled, hospitalization and death rates were based on age and risk status. All three vaccination strategies provided more health benefits than the existing vaccination situation, reducing influenza cases, complications, hospitalizations and deaths across the entire population. The strategy targeting all children under 5 years was highly cost-effective (€6/quality-adjusted life-year gained, payer perspective). The other strategies were cost saving from the payer and societal perspectives. The vaccination strategy targeting all children under 18 years was estimated to provide the most health benefits (preventing on average 1.66 million cases, 179,000 complications, 14,000 hospitalizations and 3,600 deaths due to influenza annually) and the most cost savings (annually €20.5 million and €731.3 million from payer and societal perspectives, respectively). Our analysis provides policy decision-makers with evidence supporting strategies to expand childhood influenza vaccination, to directly protect children, and indirectly all other unvaccinated age groups, in order to reduce the humanistic and economic burden on healthcare systems and society. What is the context? What is new? What is the impact?
- Open Access
German travelers’ preferences for travel vaccines assessed by a discrete choice experiment